SS&C Technologies (SSNC) Analyst Day 2024 summary

Strategic priorities and business overview

• Focus on integrating technology and services across financial services and healthcare, leveraging acquisitions, internal R&D, and product innovation to drive growth and efficiency.

• Emphasis on AI, automation, and digital workers to enhance productivity, reduce manual labor, and improve client offerings, with over 1,700 digital workers and $100M+ in savings delivered.

• Expansion into new markets and geographies, including Abu Dhabi, India, Australia, Asia, and Europe, with international revenue now 30% YTD.

• Cross-selling and upselling across a large, diversified client base of 20,000+ clients, with a holistic relationship approach and enhanced sales processes.

• Continued investment in sales force, talent, learning, diversity, product integration, and customer satisfaction to drive organic revenue growth.

Technology and innovation

• Significant R&D investment ($700M in 2024, ~$2.9B since 2020), supporting 5,500 technologists and 2,300+ applications, with a focus on scalable, secure, and standardized global platforms.

• AI and automation (Blue Prism, generative AI) are embedded in products and operations, with 57+ AI applications in development and the launch of Blue Prism NextGen.

• Launch of new platforms like Genesis, Trust Suite, and cloud-native, AI-powered solutions, integrating legacy products into unified offerings.

• Security and compliance are prioritized through proprietary tools like TARVOS and infrastructure-as-code practices, with LLM-as-a-service and enhanced auditing.

• Private cloud infrastructure supports global operations and client deployments, expanded in 2024 with new sites and enhanced security, performance, and analytics.

Financial performance and guidance

• Recurring revenues make up over 80% of the base, with high retention rates, long-term contracts, and 85% from financial services.

• Organic revenue growth guidance raised to 4%-8% annually over the next three years, driven by product integration, cross-sell, and market expansion.

• EBITDA margin expected to remain strong, targeted between 38%-43%, with productivity gains from automation and disciplined cost management.

• Over $1B returned to shareholders in 2023 and YTD 2024 via buybacks and dividends; $1B buyback authorization for 2024.

• Revenue per headcount increased 10% and facilities cost per headcount decreased 35% from 2020 to 2024.